94199-49-2 Usage
Uses
Used in Pharmaceutical Industry:
(2,3-dihydroxypropyl) hydrogen succinate is used as a building block for the synthesis of various drugs and pharmaceutical products. Its complexing properties make it valuable in the development of new medications.
Used in Polymer and Resin Production:
(2,3-dihydroxypropyl) hydrogen succinate is used in the production of certain types of polymers and resins, contributing to the creation of materials with specific properties for various applications.
Used in Food Industry:
(2,3-dihydroxypropyl) hydrogen succinate has potential applications in the food industry as an ingredient in the formulation of certain products, likely due to its chelating and complexing properties.
Used in Cosmetic Industry:
(2,3-dihydroxypropyl) hydrogen succinate also has potential applications in the cosmetic industry, where it may be used in the formulation of products to provide specific benefits based on its chemical properties.
Check Digit Verification of cas no
The CAS Registry Mumber 94199-49-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,4,1,9 and 9 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 94199-49:
(7*9)+(6*4)+(5*1)+(4*9)+(3*9)+(2*4)+(1*9)=172
172 % 10 = 2
So 94199-49-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H12O6/c8-3-5(9)4-13-7(12)2-1-6(10)11/h5,8-9H,1-4H2,(H,10,11)
94199-49-2Relevant academic research and scientific papers
Non-nucleoside reverse transcriptase inhibitors
-
, (2008/06/13)
Non-nucleoside reverse transcriptase inhibitors of formula (P-1) wherein: Ar1 is an unsaturated, optionally substituted, mono or bicyclic ring structure comprising 0 to 3 hetero atoms selected from S, O and N; Ar2 is an aromatic, optionally substituted, monocyclic ring structure comprising at least one nitrogen hetero atom and zero to two further hetero atoms selected from S, O and N; R4 and R5 are independently H or C3-C8 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C5 alkoxy, C1-C4 alkanoyloxy, C1-C4 alkylthio, amino, carboxy, carbamoyl, cyano, halo, hydroxy, aminomethyl, hydroxymethyl, carboxymethyl, or halo substituted C1-C6 alkyl mercapto, nitro; or R4 and RS join to form a 3-6 membered, optionally substituted ring structure; R6 is 0 or S; Rx is the residue of a natural or unnatural amino acid; and L* is a linker moiety which is ether-, carbonate- or ester-bound to the adjacent oxygen and ester linked to Rx; and pharmaceutically acceptable salts thereof are anti-HIV agents with favourable pharmacokinetic properties.
